MFC
Price Chart
Financials
Investment Metrics(as of 2026-06-19)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | 25.99B KRW |
| Revenue | 18.11B KRW |
| Net Income | 224.4M KRW |
| Total Assets | 34.43B KRW |
| Net Assets | 29.49B KRW |
| Employees | 70 |
| Value | |
| P/E | 115.84x |
| P/B | 0.88x |
| P/S | 1.43x |
| Profitability | |
| ROE | 0.76% |
| ROA | 0.65% |
| Op. Margin | -0.87% |
| Revenue Growth | -45.78% |
| Earnings Growth | -1850.85% |
| Financial Health | |
| Debt Ratio | 116.75% |
| Total Debt | 2.83B KRW |
| Cash | 3.64B KRW |
| Current Ratio | 3.83x |
| Performance | |
| 1Y Return | -26.67% |
| 1M Return | 12.66% |
| From 52W High | -33.22% |
| 1Y MDD | -41.64% |
| Trading | |
| Volume | 38,153 shares |
| Foreign Own. | 1.36% |
| Per Share | |
| EPS | 26 KRW |
| BPS | 3,652 KRW |
Company Info
MFC, established in 2008, is a specialized company in Active Pharmaceutical Ingredient (API) and material development and manufacturing, listed on the KOSDAQ market as a technology growth company in 2024. Utilizing organic synthesis, mass production, and new crystallization technologies, MFC develops and mass produces APIs, Key Starting Materials (KSM), and Pharmaceutical Intermediates (PI). The company produces and sells APIs for various therapeutic areas, including cardiovascular, digestive, and anti-inflammatory and analgesic treatments. MFC is pursuing market preemption by securing intellectual property rights for new crystal forms and salts in the improved new drug raw materials sector. The company is headquartered in Hwaseong-si, Gyeonggi-do.